-

Revolutionary At-Home Breast Cancer Screening, Auria®, Debuts at National Consortium of Breast Centers (NCoBC) Annual Conference

FAYETTEVILLE, Ark.--(BUSINESS WIRE)--Namida Lab, a global pioneering tear-based cancer screening, unveiled Auria®, the groundbreaking at-home biological breast cancer screening test, at the New Technology Showcase during the 32nd Annual Interdisciplinary Breast Center Conference (NCoBC) in Las Vegas.

Auria’s cutting-edge technology is poised to transform the breast cancer screening landscape by addressing the urgent need to reduce the devastating impact of breast cancer. Current data emphasizes the critical role of early breast cancer detection in saving lives, particularly for women under 45 who are often diagnosed with late-stage cancer, have a higher chance of recurrence, and account for half of the breast cancer fatalities. ¹ With Auria’s availability for women starting at age 30, it empowers younger women to proactively manage their breast health through convenient and accessible screening options.

“Auria caters to the needs of modern women who demand health screening on their terms – convenient, user-friendly, timely, and personalized, with expert analysis that takes their individual risk profiles into account,” said presenter Dr. Anna Daily, Ph.D., Namida’s Chief Scientific Officer and Inventor of Auria, “Auria has been meticulously designed and implemented to address a critical pain point for women and healthcare providers alike.”

Breast Centers attending the conference were invited to join the Auria Referral Network to boost patient engagement and minimize missed mammogram appointments. The Auria test includes a clinical consultation to review results, answer questions, and discuss next steps in breast health. Breast Centers in the Auria Referral Network allow women to plan their next steps in a center that is familiar with Auria.

Press Images

References:

  1. Non-BRCA Early-Onset Breast Cancer in Young Women
    Yiming Gao, Naziya Samreen, and Samantha L. Heller
    RadioGraphics 2022 42:1, 5-22

About Namida Lab

Namida Lab, Inc., is a product-stage biotechnology company specializing in the development and commercialization of early cancer detection proteomics tests. Namida’s first product is Auria®, the first at-home biological breast cancer screening test. Auria is available at auria.care, Walmart, and Amazon.

Contacts

Saul Robles
Senior Marketing Manager, Namida Lab, Inc.
+1-479-334-2828
saul@namidalab.com

Namida Lab, Inc.


Release Summary
Namida Lab has introduced Auria, an at-home biological breast cancer screening test that uses tear-based cancer screening technology.
Release Versions

Contacts

Saul Robles
Senior Marketing Manager, Namida Lab, Inc.
+1-479-334-2828
saul@namidalab.com

More News From Namida Lab, Inc.

Namida Wins Top Intelligent Diagnostics Award for Auria® at Prestigious 2023 Edison Awards™ Honors

FORT MYERS, Fla.--(BUSINESS WIRE)--Namida Lab's innovative biological breast cancer screening technology, Auria®, has been awarded the prestigious Gold prize for Intelligent Diagnostics at the 36th annual Edison Awards in Fort Myers, Florida. The at-home biological breast cancer screening test, which is powered by tears, was named winner in the Health, Medical & Biotech Intelligent Design category, along with finalists Galleri® by GRAIL and Pharmacogenomic Testing by GeneIQ. Namida Founder...

Namida Lab Drives Expansion by Appointing Advisory Board and Announcing Organizational Changes

FAYETTEVILLE, Ark.--(BUSINESS WIRE)--Namida Lab, the world leader in tear-based cancer screening, announces the appointment of an advisory board composed of leaders from breast oncology and radiology, healthcare strategy, and consumer marketing fields. The establishment of the advisory board, along with promotions of key staff and new hires, will accelerate growth in establishing innovative and accessible screening tools for the future of whole health through preventative care. Clinical Advisor...

Namida Lab Announces Poster Presentation at the 2022 San Antonio Breast Cancer Symposium

FAYETTEVILLE, Ark.--(BUSINESS WIRE)--Namida Lab, the world leader in tear-based diagnostics, presented research on tear-based breast cancer biomarkers used for at-home testing with Auria....
Back to Newsroom